))
Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs
Manage episode 301442543 series 2838329
コンテンツは VJHemOnc によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、VJHemOnc またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Janus kinase (JAK) inhibitors are becoming an increasingly prominent class of drug in the treatment of myeloproliferative neoplasms (MPNs), in particular for the management of myelofibrosis symptoms. With the FDA approval of ruxolitinib in 2011 followed by the approval of fedratinib in 2019, JAK inhibitors are already established in the myelofibrosis treatment landscape; however, studies investigating novel JAK inhibitors could potentially lead to further approvals. Both pacritinib and momelotinib have demonstrated promising results in the PERSIST-2 trial and the SIMPLIFY-1 and SIMPLIFY-2 trials and continue to be explored in the ongoing MOMENTUM and PACIFICA trials, respectively.
In this podcast, Ruben Mesa, MD, of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, Aaron Gerds, MD, of the Cleveland Clinic, Cleveland, OH, and Abdulraheem Yacoub, MD, MBBS, of The University of Kansas, Westwood, KS, discuss the latest updates on JAK inhibitors for the treatment of MPNs, as presented at the Texas MPN Workshop: Second Annual Meeting and Workshop 2021.
201 つのエピソード
シェア
